Tanezumab Dances Through Back Pain Studies With “Acceptable” Safety Answers
Executive Summary
In its latest TANGO trial for chronic lower back pain, Eli Lilly and Pfizer’s tanezumab has shown efficacy at 10 mg, but its 5 mg dose missed the statistically significant mark. Vitally, analysts are encouraged by safety data.
You may also be interested in...
Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results
Larger of two doses of the NGF inhibitor hit two efficacy endpoints, but the rate of joint health outcomes on a composite measure was higher than control by a statistically significant margin.
Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain
The companies reported positive Phase III data testing the nerve growth factor inhibitor in patients with chronic pain, but the efficacy appears modest and safety will remain a question until long-term Phase III data read out. The companies are focused on a lower 1 mg dose.
Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?
Pfizer and Lilly said tanezumab reduced pain in a Phase III osteoarthritis study, but safety is the biggest question for NGF inhibitors. Yet, while Regeneron and Teva discontinued dosing for their fasinumab at its highest dose, tanezumab was effective at both doses in its first Phase III test.